Astria Therapeutics Inc (ATXS) — Cash Flow-to-Debt Ratio
Latest as of September 2025:
-0.84x
Astria Therapeutics Inc (ATXS) has a Cash Flow-to-Debt Ratio of -0.84x as of September 2025, meaning its operating cash flow of $-32.30 Million could theoretically repay -1% of its total liabilities ($38.61 Million) in one year. See how financially flexible is Astria Therapeutics Inc to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-0.84x
Operating CF / Total Liabilities
Operating Cash Flow
$-32.30 Million
USD
Total Liabilities
$38.61 Million
USD
Data as of
Sep 2025
Most recent filing
Astria Therapeutics Inc Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for Astria Therapeutics Inc across 13 annual periods. For the full cash flow conversion analysis, see Astria Therapeutics Inc (ATXS) cash conversion ratio.
Annual Cash Flow-to-Debt Ratio for Astria Therapeutics Inc (2012–2024)
Year-by-year debt coverage analysis for Astria Therapeutics Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -3.52x | $-81.21 Million | $23.10 Million | ▲ +40.7% |
| 2023 | -5.93x | $-68.44 Million | $11.55 Million | ▼ -28.2% |
| 2022 | -4.62x | $-43.53 Million | $9.42 Million | ▲ +20.2% |
| 2021 | -5.79x | $-30.15 Million | $5.20 Million | ▼ -21.1% |
| 2020 | -4.79x | $-32.48 Million | $6.79 Million | ▼ -9.2% |
| 2019 | -4.38x | $-26.57 Million | $6.06 Million | ▲ +21.0% |
| 2018 | -5.55x | $-23.46 Million | $4.23 Million | ▼ -26.3% |
| 2017 | -4.40x | $-26.84 Million | $6.11 Million | ▼ -48.8% |
| 2016 | -2.95x | $-32.86 Million | $11.12 Million | ▼ -36.1% |
| 2015 | -2.17x | $-29.79 Million | $13.73 Million | ▼ -846.3% |
| 2014 | -0.23x | $-20.41 Million | $89.02 Million | ▼ -16.6% |
| 2013 | -0.20x | $-16.37 Million | $83.19 Million | ▲ +97.4% |
| 2012 | -7.69x | $-15.58K | $2.03K | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.